Patents by Inventor Jay Marshall Feingold

Jay Marshall Feingold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cut-point in PTEN protein expression that accurately identifies tumors and is predictive of drug response to a pan-ErbB inhibitor
    Patent number: 8338456
    Abstract: A cut-point in the quantitative measurement of PTEN protein expression that accurately identifies tumors with two inactivated alleles of the PTEN gene. Patients with a normalized PTEN score of PTEN null will be treated with a pan-ErbB tyrosine kinase inhibitor. A normalized PTEN protein expression score is obtained by comparing the tumor PTEN OD expression value with the non-malignant PTEN OD expression value.
    Type: Grant
    Filed: January 4, 2011
    Date of Patent: December 25, 2012
    Assignee: Wyeth LLC
    Inventors: Christina Marie Coughlin, Jay Marshall Feingold, Daniel Stephen Johnston, Anna Berkenblit, Andrew Louis Strahs, Charles Michael Zacharchuk
  • CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR
    Publication number: 20120010240
    Abstract: A cut-point in the quantitative measurement of PTEN protein expression that accurately identifies tumors with two inactivated alleles of the PTEN gene. Patients with a normalized PTEN score of PTEN null will be treated with a pan-ErbB tyrosine kinase inhibitor. A normalized PTEN protein expression score is obtained by comparing the tumor PTEN OD expression value with the non-malignant PTEN OD expression value.
    Type: Application
    Filed: January 4, 2011
    Publication date: January 12, 2012
    Applicant: Wyeth LLC
    Inventors: Christina Marie Coughlin, Jay Marshall Feingold, Daniel Steven Johnston, Anna Berkenblit, Andrew Louis Strahs, Charles Michael Zacharchuk
  • Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
    Patent number: 7727968
    Abstract: Methods of treatment and pharmaceutical combinations are provided for the treatment of acute leukemia, such as acute myelogenous leukemia, and myelodysplastic syndrome. The methods of treatment and pharmaceutical combinations employ an anti-CD33 cytotoxic conjugate in combination with at least one compound selected from the group consisting of an anthracycline and a pyrimidine or purine nucleoside analog. Preferred methods of treatment and pharmaceutical combinations employ gemtuzumab ozogamicin, daunorubicin, and cytarabine.
    Type: Grant
    Filed: June 11, 2007
    Date of Patent: June 1, 2010
    Assignee: Wyeth LLC
    Inventors: Jay Marshall Feingold, Matthew L. Sherman, Lance H. Leopold, Mark Berger
  • ANTI-TUMOR ACTIVITY OF CCI-779 IN PAPILLARY RENAL CELL CANCER
    Publication number: 20080255177
    Abstract: This invention provides the method or use of CCI-779 in the treatment of papillary renal cell carcinoma.
    Type: Application
    Filed: April 8, 2008
    Publication date: October 16, 2008
    Applicant: Wyeth
    Inventors: GARY DUKART, James Joseph Gibbons, Anna Berkenblit, Jay Marshall Feingold
  • Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
    Publication number: 20040152632
    Abstract: Methods of treatment and pharmaceutical combinations are provided for the treatment of acute leukemia, such as acute myelogenous leukemia, and myelodysplastic syndrome. The methods of treatment and pharmaceutical combinations employ an anti-CD33 cytotoxic conjugate in combination with at least one compound selected from the group consisting of an anthracycline and a pyrimidine or purine nucleoside analog. Preferred methods of treatment and pharmaceutical combinations employ gemtuzumab ozogamicin, daunorubicin, and cytarabine.
    Type: Application
    Filed: November 4, 2003
    Publication date: August 5, 2004
    Applicant: Wyeth
    Inventor: Jay Marshall Feingold